• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Intraday Session

    3/23/23 1:31:29 PM ET
    $AVRO
    $CDTX
    $ERYP
    $GBIO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AVRO alert in real time by email

    Gainers

    • ZyVersa Therapeutics (NASDAQ:ZVSA) shares increased by 31.4% to $2.14 during Thursday's regular session. As of 13:30 EST, this security is trading at a volume of 8.9 million shares, making up 2630.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $19.7 million.
    • Jaguar Health (NASDAQ:JAGX) shares increased by 25.92% to $1.02. The current volume of 3.2 million shares is 317.5% of Jaguar Health's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $2.0 million.
    • Erytech Pharma (NASDAQ:ERYP) stock moved upwards by 24.95% to $0.99. The company's market cap stands at $30.7 million.
    • HTG Molecular Diagnostics (NASDAQ:HTGM) stock increased by 24.81% to $3.42. Trading volume for HTG Molecular Diagnostics's stock is 332.9K as of 13:30 EST. This is 47.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $3.4 million.
    • Generation Bio (NASDAQ:GBIO) shares rose 24.74% to $4.84. Trading volume for this security as of 13:30 EST is 10.4 million, which is 4906.8% of its average full-day volume over the last 100 days. The company's market cap stands at $288.7 million.
    • scPharmaceuticals (NASDAQ:SCPH) stock rose 23.98% to $8.58. As of 13:30 EST, scPharmaceuticals's stock is trading at a volume of 602.6K, which is 119.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $292.1 million. As per the news, the Q4 earnings report came out yesterday.

    Losers

    • Vicarious Surgical (NYSE:RBOT) stock fell 32.5% to $1.53 during Thursday's regular session. As of 13:30 EST, this security is trading at a volume of 3.3 million shares, making up 1178.6% of its average full-day volume over the last 100 days. The company's market cap stands at $193.0 million.
    • Surrozen (NASDAQ:SRZN) stock declined by 23.44% to $0.76. As of 13:30 EST, this security is trading at a volume of 634.1K shares, making up 91.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $22.5 million. As per the news, the Q4 earnings report came out yesterday.
    • Avrobio (NASDAQ:AVRO) stock fell 22.16% to $0.96. Trading volume for this security as of 13:30 EST is 879.9K, which is 69.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $41.9 million. As per the press release, Q4 earnings came out today.
    • Cidara Therapeutics (NASDAQ:CDTX) stock fell 20.79% to $1.5. As of 13:30 EST, this security is trading at a volume of 8.8 million shares, making up 315.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $124.4 million. The company's, Q4 earnings came out today.
    • SenesTech (NASDAQ:SNES) shares declined by 19.15% to $1.52. SenesTech's stock is trading at a volume of 193.0K shares as of 13:30 EST. This is 109.4% of its average full-day volume over the last 100 days. The company's market cap stands at $3.1 million.
    • Marker Therapeutics (NASDAQ:MRKR) stock fell 18.35% to $0.98. The current volume of 231.4K shares is 526.3% of Marker Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $8.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AVRO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVRO
    $CDTX
    $ERYP
    $GBIO

    CompanyDatePrice TargetRatingAnalyst
    Surrozen Inc.
    $SRZN
    2/19/2026$40.00Overweight
    Cantor Fitzgerald
    Generation Bio Co.
    $GBIO
    12/16/2025$5.50Neutral → Outperform
    Wedbush
    Generation Bio Co.
    $GBIO
    12/16/2025$5.00Buy → Hold
    Jefferies
    Cidara Therapeutics Inc.
    $CDTX
    11/17/2025Overweight → Equal-Weight
    Morgan Stanley
    Cidara Therapeutics Inc.
    $CDTX
    11/17/2025Overweight → Neutral
    Analyst
    Cidara Therapeutics Inc.
    $CDTX
    11/17/2025Outperform → Sector Perform
    RBC Capital Mkts
    Cidara Therapeutics Inc.
    $CDTX
    10/16/2025$190.00Overweight
    Morgan Stanley
    Cidara Therapeutics Inc.
    $CDTX
    10/10/2025$200.00Overweight
    Analyst
    More analyst ratings

    $AVRO
    $CDTX
    $ERYP
    $GBIO
    SEC Filings

    View All

    Vicarious Surgical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - Vicarious Surgical Inc. (0001812173) (Filer)

    3/9/26 4:17:50 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    SEC Form 10-K filed by Vicarious Surgical Inc.

    10-K - Vicarious Surgical Inc. (0001812173) (Filer)

    3/9/26 4:16:00 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    Jaguar Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation

    8-K - Jaguar Health, Inc. (0001585608) (Filer)

    3/9/26 9:05:16 AM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVRO
    $CDTX
    $ERYP
    $GBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Surrozen with a new price target

    Cantor Fitzgerald initiated coverage of Surrozen with a rating of Overweight and set a new price target of $40.00

    2/19/26 7:52:22 AM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Generation Bio upgraded by Wedbush with a new price target

    Wedbush upgraded Generation Bio from Neutral to Outperform and set a new price target of $5.50

    12/16/25 12:29:16 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Generation Bio downgraded by Jefferies with a new price target

    Jefferies downgraded Generation Bio from Buy to Hold and set a new price target of $5.00

    12/16/25 8:41:52 AM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVRO
    $CDTX
    $ERYP
    $GBIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SenesTech to Report Fourth Quarter and Fiscal Year 2025 Financial Results on Thursday, March 12, 2026

    Financial results to be released after market close; Conference call to be conducted at 5:00 p.m. Eastern timePHOENIX, March 9, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, will report financial results for its fourth quarter and fiscal year 2025, ended December 31, 2025, after the market close on Thursday, March 12, 2026. The Company has scheduled a conference call that same day, Thursday, March 12, 2026, at 5:00 pm ET, to review the results. Fourth Quarter and Fiscal Year 2024 Conference Call DetailsDa

    3/9/26 4:15:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Vicarious Surgical Receives Delisting Notice From NYSE

    Vicarious Surgical Inc. (NYSE:RBOT) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that on March 3, 2026, it received a notice (the "Notice") from the New York Stock Exchange (the "NYSE") that the NYSE has commenced the process of delisting the Company's Class A common stock, par value $0.0001 per share (the "Common Stock"). Trading on the Company's Common Stock on the NYSE was suspended after market close on March 3, 2026. The NYSE has determined that the Company has fallen below the continued listing standard, requiring listed companies to maintain an average global market capitalization over a con

    3/4/26 7:00:00 AM ET
    $RBOT
    Industrial Specialties
    Health Care

    Surrozen to Present at Upcoming Healthcare Investor Conference

    SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference. TD Cowen 46th Annual Healthcare Conference on Wednesday, March 4, 2026 Fireside Chat at 1:10 PM Eastern Time / 10:10 AM Pacific Time Interested parties may access the live audio webcast for the conference via the Investors section of the Surrozen website at https://investors.surrozen.com

    2/25/26 4:05:00 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AVRO
    $CDTX
    $ERYP
    $GBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President Sachs Adam David sold $1,967 worth of shares (942 units at $2.09), decreasing direct ownership by 2% to 46,943 units (SEC Form 4)

    4 - Vicarious Surgical Inc. (0001812173) (Issuer)

    2/24/26 4:59:00 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    Chief Technology Officer Khalifa Sammy sold $1,571 worth of shares (754 units at $2.08), decreasing direct ownership by 2% to 32,869 units (SEC Form 4)

    4 - Vicarious Surgical Inc. (0001812173) (Issuer)

    2/24/26 4:58:35 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    Large owner Glenbrook Capital Management bought $200,635 worth of shares (85,901 units at $2.34) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/19/26 7:57:41 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $AVRO
    $CDTX
    $ERYP
    $GBIO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for FUROSCIX issued to SCPHARMACEUTICALS INC

    Submission status for SCPHARMACEUTICALS INC's drug FUROSCIX (ORIG-1) with active ingredient FUROSEMIDE has changed to 'Approval' on 10/07/2022. Application Category: NDA, Application Number: 209988, Application Classification: Type 3 - New Dosage Form

    10/11/22 1:54:57 PM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVRO
    $CDTX
    $ERYP
    $GBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Glenbrook Capital Management bought $200,635 worth of shares (85,901 units at $2.34) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/19/26 7:57:41 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Large owner Glenbrook Capital Management bought $56,667 worth of shares (31,346 units at $1.81) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/13/26 5:20:17 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Large owner Tcg Crossover Gp Ii, Llc bought $444,844 worth of shares (18,856 units at $23.59) (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    2/13/26 4:19:53 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AVRO
    $CDTX
    $ERYP
    $GBIO
    Leadership Updates

    Live Leadership Updates

    View All

    NodThera Appoints Geoff McDonough, M.D., as Chief Executive Officer

    Dr. McDonough brings global company-building, commercial strategy, and R&D leadership experience to the Company ahead of key clinical milestones NodThera plans to report results from two Phase 2 cardiometabolic trials RESOLVE-1 and RESOLVE-2 in mid-2026 and third quarter 2026 respectively Company preparing to begin cardiometabolic Phase 3 trial in 1H 2027 BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- NodThera, the leading clinical-stage NLRP3 company developing a portfolio of best-in-class brain-penetrant and immune-targeted oral inhibitors to address unmet needs in cardiometabolic and neuroinflammatory diseases driven by the NLRP3/IL-6/IL-1 inflammation pathway, announced the appointment o

    2/4/26 8:00:00 AM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs

    Experienced industry leader brings extensive expertise in leading breakthrough therapies through clinical development to marketing approval Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced the appointment of Antoinette Paone as Chief Development Officer ("CDO") and Head of Regulatory Affairs. Ms. Paone brings extensive experience leading regulatory strategy from clinical development through approval, including her work on Kalydeco and Orkambi at Vertex Pharmaceuticals (NASDAQ:VRTX). She joins Satellos from Generation Bio (NASDAQ:G

    1/29/26 7:00:00 AM ET
    $GBIO
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SenesTech Announces CEO Transition Plan

    Board To Initiate Search For New Leadership As Current CEO Plans Retirement Dr. Jamie Bechtel Named Interim Executive Chair To Further Support Transition PHOENIX, Jan. 28, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a pioneer in fertility control solutions for managing rodent populations, today announced that Joel Fruendt, President and Chief Executive Officer, has informed the Board of Directors of his intent to retire. The Board will commence a formal search for a successor. Mr. Fruendt will continue to serve as President and CEO until the search is completed or until June 30, 2026, whichever occurs first.

    1/28/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $AVRO
    $CDTX
    $ERYP
    $GBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Generation Bio Co.

    SC 13G/A - Generation Bio Co. (0001733294) (Subject)

    12/9/24 6:18:02 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Cidara Therapeutics Inc.

    SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

    12/9/24 5:37:15 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Cidara Therapeutics Inc.

    SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

    12/4/24 4:15:14 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AVRO
    $CDTX
    $ERYP
    $GBIO
    Financials

    Live finance-specific insights

    View All

    SenesTech to Report Fourth Quarter and Fiscal Year 2025 Financial Results on Thursday, March 12, 2026

    Financial results to be released after market close; Conference call to be conducted at 5:00 p.m. Eastern timePHOENIX, March 9, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, will report financial results for its fourth quarter and fiscal year 2025, ended December 31, 2025, after the market close on Thursday, March 12, 2026. The Company has scheduled a conference call that same day, Thursday, March 12, 2026, at 5:00 pm ET, to review the results. Fourth Quarter and Fiscal Year 2024 Conference Call DetailsDa

    3/9/26 4:15:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Vicarious Surgical Receives Delisting Notice From NYSE

    Vicarious Surgical Inc. (NYSE:RBOT) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that on March 3, 2026, it received a notice (the "Notice") from the New York Stock Exchange (the "NYSE") that the NYSE has commenced the process of delisting the Company's Class A common stock, par value $0.0001 per share (the "Common Stock"). Trading on the Company's Common Stock on the NYSE was suspended after market close on March 3, 2026. The NYSE has determined that the Company has fallen below the continued listing standard, requiring listed companies to maintain an average global market capitalization over a con

    3/4/26 7:00:00 AM ET
    $RBOT
    Industrial Specialties
    Health Care

    XOMA Royalty Enters into Agreement to Acquire Generation Bio

    - Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio's collaboration with Moderna - - Generation Bio's cell-targeted lipid nanoparticles (ctLNP) delivery platform for small interfering RNA (siRNA) and other nucleic acid therapies to be included in XOMA Royalty's portfolio - EMERYVILLE, Calif. and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA), the biotech royalty aggregator, announced today it has entered into an agreement to acquire Generation Bio Co. ("Generation Bio") (NASDAQ:GBIO) for a cash price of $4.2913 per share at the closing of the merger. Generation Bio stockholders

    12/15/25 5:00:00 PM ET
    $GBIO
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care